<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Virginia skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Virginia</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="popup"><DIV><P>iGEM 2015</P></DIV><P>Welcome the University of Virginia iGEM 2015 Wiki! Use the navigation bar at the top of every page to move between pages. Please let us know if you have any comments or questions about our project by visiting the “Contact Us” page.</P><P>(click to close)</P></DIV><DIV id="top-part"><P id="above-nav">University of Virginia iGEM 2015</P></DIV><DIV class="nav"><DIV class="container"><UL class="pull-left"><LI><A href="/Team:Virginia">Home</A></LI></UL><UL class="pull-right"><LI><A href="/Team:Virginia/Team">Team</A></LI><LI><A href="/Team:Virginia/Project">Project</A></LI><LI><A href="/Team:Virginia/Practices">Policy and Practices</A></LI><LI><A href="/Team:Virginia/Attributions">Attributions</A></LI><LI><A href="/Team:Virginia/Contact_us">Contact Us</A></LI></UL></DIV></DIV><DIV class="back"><DIV class="jumbotron"><H2>
					House of Carbs
					<P>A Novel Solution to Minimizing Postprandial Hyperglycemic Spikes</P></H2></DIV><DIV id="description-wrapper"><DIV id="description-text-wrapper"><H1>Project Overview</H1><H3 id="h3-1">The Problem: Diabetes Mellitus and Hyperglycemia</H3><A href="javascript:void(0);"><DIV class="minimize" id="min1"><P>SHOW LESS</P></DIV></A><A href="javascript:void(0);"><DIV class="maximize" id="max1"><P>SHOW MORE</P></DIV></A><DIV id="des1"><P>From diabetes mellitus a number of devastating complications, such as amputations, blindness, crippling neuropathies, and many others, can arise from increased blood sugar levels on a regular basis, but many of 
						the major complications of diabetes arise from drastic fluctuations in the blood glucose 
						level (Ceriello et al., 2012). Up to two-thirds of people with diabetes die of 
						cardiovascular disease (CVD) brought about by diabetes-related macrovascular diseases 
						(Deshpande et al. 2008). In fact, the risk for cardiovascular disease mortality is 2 to 4 
						times higher in people with diabetes than in people who do not have diabetes. 
						Additionally, diabetic retinopathy is the most common microvascular complication 
						among people with diabetes and results in more than 10,000 new cases of blindness per 
						year. Retinopathy is associated with prolonged hyperglycemia; it is slow to develop, and 
						there is some evidence that it can begin to develop as early as 7 years before clinical 
						diagnosis of diabetes (Deshpande et al., 2008).
					</P><P>Postprandial (post-meal) blood sugar spikes specifically are one of the most 
						damaging complications of diabetes (Parkin et al., 2002). Many diabetics are able to 
						effectively manage post-meal glycemic spikes with self-administered doses of insulin, 
						but these hyperglycemic incidents still kill more Americans per year than any other 
						diabetes-related complications (Parkin et al., 2002). Arguably, the gravest consequence of 
						glycemic spikes in diabetes patients is the development of progressive macrovascular 
						disease (MVD), which affects the large blood vessels of the body, hardening and 
						blocking these vessels (Ceriello et al., 2012). MVD is the leading cause of death among 
						T2DM patients in the United States, causing up to 65% of diabetes-related deaths, making it a huge target for diabetes treatments research (Deshpande et al., 2008). MVD 
						also frequently leads to other severe complications such as ischemia in the extremities 
						and blindness (Haffner et al., 1998).
					</P></DIV><H3 id="h3-2">Controlling Hyperglycemic Spikes</H3><DIV id="des2"><A href="javascript:void(0);"><DIV class="minimize" id="min2"><P>SHOW LESS</P></DIV></A><A href="javascript:void(0);"><DIV class="maximize" id="max2"><P>SHOW MORE</P></DIV></A><P>For many T1DM and T2DM patients, it has been shown that the regular 
						control and management of blood glucose levels prevents many of the vascular 
						complications of the disease, but most of the time control over glucose is difficult to 
						attain because the self-dosing insulin treatment system that a lot of moderately to 
						severely sick diabetes patients use is often hard to calibrate and use (Parkin et al., 2002).
					</P><P>Compared to sucrose-rich food, starch-rich food has been found to create less 
						fluctuation in blood glucose levels, and thus is beneficial to diabetes patients and 
						hyperglycemia patients. There is evidence that this flatter response caused by a starch
						rich meal is associated with the slower rate of digestion of complex sugars versus simple 
						sugars (Jenkins, Wolever, &amp; Jenkins, 1988). Thus, if some of the simple sugars are first 
						converted into complex saccharides inside the E. coli and then released back into small 
						intestine, a similar flatter glycemic response will take place, which will be beneficial to 
						the patients.
					</P></DIV><H3 id="h3-3">Our Devices</H3><DIV id="des3"><A href="javascript:void(0);"><DIV class="minimize" id="min3"><P>SHOW LESS</P></DIV></A><A href="javascript:void(0);"><DIV class="maximize" id="max3"><P>SHOW MORE</P></DIV></A><P style="margin-bottom:30px;"> We have assembled one plasmid with genes that dictate a controllable level of simple sugars uptake and one plasmid to produce glucan and fructan from simple sugars and then lyse to release the complex sugars back into the environment. In essence, this microbial device runs on two genetic devices -- an uptake circuit and a polymerization circuit. </P></DIV><P style="font-style:italic; border-top:1px dotted #007bb6"> In order to learn more details, please visit the <A href="/Team:Virginia/Project">Project page.</A></P><A href="javascript:void(0);"><DIV id="ref-button"><P>Show References</P></DIV></A><A href="javascript:void(0);"><DIV id="ref-button2"><P>Hide References</P></DIV></A><DIV id="ref-content"><H3>References</H3><P>A. Ceriello, S. Colagiuri, (2011). Guideline for management of postmeal glucose in 
							diabetes. International Diabetes Federation Guideline Development Group, 
							http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf , 
							Accessed May. 6th, 2015
						</P><P>American Diabetes Association (2014). National Diabetes Statistics Report.
							http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf 
							Accessed May. 5th, 2015
						</P><P>Anal, A. K., &amp; Singh, H. (2007). Recent advances in microencapsulation of probiotics for 
							industrial applications and targeted delivery. Trends in Food Science &amp; 
							Technology, 18(5), 240–251. http://doi.org/10.1016/j.tifs.2007.01.004
						</P><P>Anan, F., Masaki, T., Eto, T., Fukunaga, N., Iwao, T., Kaneda, K., ... Yoshimatsu, H. 
							(2008). Postchallenge Plasma Glucose and Glycemic Spikes Are Associated with 
							Pulse Pressure in Patients with Impaired Glucose Tolerance and Essential 
							Hypertension. Hypertension Research, 31(8), 1565–1571. 
							http://doi.org/10.1291/hypres.31.1565
						</P><P>AHFS Consumer Medication Information [Internet]. Bethesda (MD): American Society 
							of Health-System Pharmacists, Inc.; ©2008. Acarbose; [revised 2015 Feb. 15; 
							reviewed 2015 Apr. 28; cited 2015 May. 3]; Available from: 
							http://www.nlm.nih.gov/medlineplus/druginfo/meds/ a696015.html
						</P><P>AHFS Consumer Medication Information [Internet]. Bethesda (MD): American Society 
							of Health-System Pharmacists, Inc.; ©2008. Pramlintide; [revised 2015 Feb. 15; 
							reviewed 2015 Apr. 28; cited 2015 May. 3]; Available from:
							http://www.nlm.nih.gov/medlineplus/druginfo/meds/a605031.html
						</P><P>Banguela, A., Arrieta, J. G., Rodríguez, R., Trujillo, L. E., Menéndez, C., &amp; Hernández, 
							L. (2011). High levan accumulation in transgenic tobacco plants expressing the 
							Gluconacetobacter diazotrophicus levansucrase gene. Journal of Biotechnology, 
							154(1), 93–98. http://doi.org/10.1016/j.jbiotec.2011.04.007
						</P><P>Barr EL, Zimmet PZ, Welborn TA et al. (2007). &quot;Risk of cardiovascular and all-cause 
							mortality in individuals with diabetes mellitus, impaired fasting glucose, and 
							impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study 
							(AusDiab)&quot;. Circulation 116 (2): 151–7.
						</P><P>Bernard, A. M., Anderson, L., Cook, C. B., &amp; Phillips, L. S. (1999). What do internal 
							medicine residents need to enhance their diabetes care? Diabetes Care, 22(5), 
							661–666. http://doi.org/10.2337/diacare.22.5.661
						</P><P>Boada C, Martínez-Moreno J. Pathophysiology of diabetes mellitus type 2: beyond the 
							duo &quot;insulin resistance-secretion deficit.&quot;. Nutricion Hospitalaria [serial online]. 
							March 2, 2013;28:78-87. Available from: Fuente Académica, Ipswich, MA. 
							Accessed April 16, 2015.
						</P><P>B. Göke, H. F. (1995). Voglibose (AO128) Is an Efficient α-Glucosidase Inhibitor and 
							Mobilizes the Endogenous GLP-1 Reserve. Digestion, 56(6), 493–501. 
							http://doi.org/10.1159/000201282
						</P><P>Brown, J. B., Harris, S. B., Webster-Bogaert, S., Wetmore, S., Faulds, C., &amp; Stewart, M. 
							(2002). The role of patient, physician and systemic factors in the management of 
							type 2 diabetes mellitus. Family Practice, 19(4), 344–349. 
							http://doi.org/10.1093/fampra/19.4.344
						</P><P>Butterworth, P. J., Warren, F. J., &amp; Ellis, P. R. (2011). Human α-amylase and starch 
							digestion: An interesting marriage. Starch - Stärke, 63(7), 395–405. 
							http://doi.org/10.1002/star.201000150
						</P><P>Centers for Disease Control and Prevention. (2014). National Diabetes Statistics Report.</P><P>Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., &amp; Laakso, M. (2002). 
							Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM 
							randomised trial. The Lancet, 359(9323), 2072–2077. 
							http://doi.org/10.1016/S0140-6736(02)08905-5
						</P><P>Chiasson, J.-L., Josse, R. G., Hunt, J. A., Palmason, C., Rodger, N. W., Ross, S. A., ... 
							Wolever*, T. M. S. (1994). The Efficacy of Acarbose in the Treatment of Patients 
							with Non–Insulin-Dependent Diabetes Mellitus: A Multicenter, Controlled 
							Clinical Trial. Annals of Internal Medicine, 121(12), 928–935. 
							http://doi.org/10.7326/0003-4819-121-12-199412150-00004
							Crude and Age-Adjusted Rate per 100 of Civilian, Noninstitutionalized Population with 
							Diagnosed Diabetes, United States, 1980–2011. (2014, September 5). Retrieved 
							April 24, 2015, from 
							http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm
						</P><P>Dedonder, R. 1966. Levansucrase from Bacillus subtilis. Methods Enzymol. 8:500–505.</P><P>Deshpande, A. D., Harris-Hayes, M., &amp; Schootman, M. (2008). Epidemiology of diabetes 
							and diabetes-related complications. Physical therapy, 88(11), 1254-1264.
						</P><P>D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, T.J. Orchard, et al., 
							Intensive diabetes treatment and cardiovascular disease in patients with type 1 
							diabetes, N Engl J Med, 353 (2005), pp. 2643–2653
						</P><P>D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF diabetes atlas: global estimates of the 
							prevalence of diabetes for 2011 and 2030 Diabetes Res Clin Pract, 94 (2011), pp. 
							311–321
						</P><P>Duncan, A. E. (2012). Hyperglycemia and Perioperative Glucose Management.Current 
							Pharmaceutical Design, 18(38), 6195–6203.
						</P><P>Edelman, P. S., Maier, H., &amp; Wilhelm, K. (2012). Pramlintide in the Treatment of 
							Diabetes Mellitus. BioDrugs, 22(6), 375–386. http://doi.org/10.2165/0063030-
							200822060-00004
						</P><P>Ferraris, R. P., Yasharpour, S. A. S. A. N., Lloyd, K. C., Mirzayan, R. A. F. F. Y., &amp; 
							Diamond, J. M. (1990). Luminal glucose concentrations in the gut under normal 
							conditions. American Journal of Physiology-Gastrointestinal and Liver 
							Physiology, 259(5), G822-G837.
						</P><P>Gay, P., Le Coq, D., Steinmetz, M., Ferrari, E., &amp; Hoch, J. A. (1983). Cloning structural 
							gene sacB, which codes for exoenzyme levansucrase of Bacillus subtilis: 
							expression of the gene in Escherichia coli. Journal of bacteriology,153(3), 1424-
							1431.
						</P><P>Gray, G. M., &amp; Ingelfinger, F. J. (1966). Intestinal absorption of sucrose in man: 
							interrelation of hydrolysis and monosaccharide product absorption. Journal of 
							Clinical Investigation, 45(3), 388.
						</P><P>Grant, R. W., Buse, J. B., &amp; Meigs, J. B. (2005). Quality of Diabetes Care in U.S. 
							Academic Medical Centers Low rates of medical regimen change. Diabetes Care, 
							28(2), 337–442. http://doi.org/10.2337/diacare.28.2.337
						</P><P>Grant, R. W., Pirraglia, P. A., Meigs, J. B., &amp; Singer, D. E. (2004). Trends in complexity 
							of diabetes care in the United States from 1991 to 2000. Archives of Internal 
							Medicine, 164(10), 1134–1139. http://doi.org/10.1001/archinte.164.10.1134
						</P><P>Halschou, K., Bukhave, K., &amp; Rikardt, J. (2012). Intestinal Disaccharidase Activity and 
							Uptake of Glucose from Sucrose. In S. Chackrewarthy (Ed.), Glucose Tolerance. 
							InTech. Retrieved from http://www.intechopen.com/books/glucose-
							tolerance/intestinal-disaccharidase-activity-and-uptake-of-glucose-from-sucrose
						</P><P>Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. Journal 
							of Molecular Biology, 166(4), 557–580.
						</P><P>Hoffmann, J., &amp; Spengler, M. (1997). Efficacy of 24-Week Monotherapy With Acarbose, 
							Metformin, or Placebo in Dietary-Treated NIDDM Patients: The Essen-II Study. 
							The American Journal of Medicine, 103(6), 483–490. 
							http://doi.org/10.1016/S0002-9343(97)00252-0
							Intensive blood-glucose control with sulphonylureas or insulin compared with 
							conventional treatment and risk of complications in patients with type 2 diabetes 
							(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
						</P><P>Jenkins, D. J. A., Wolever, T. M. S., &amp; Jenkins, A. L. (1988). Starchy Foods and 
							Glycemic Index. Diabetes Care, 11(2), 149–159. 
							http://doi.org/10.2337/diacare.11.2.149
						</P><P>Jones, M. C. (2007). Therapies for diabetes: pramlintide and exenatide. American Family 
							Physician, 75(12), 1831–1835.
						</P><P>J Reizer, S. L. S. (1992). Functional interactions between proteins of the 
							phosphoenolpyruvate:sugar phosphotransferase systems of Bacillus subtilis and 
							Escherichia coli. The Journal of Biological Chemistry, 267(13), 9158–69.
							Jenkins, D. J., Wolever, T. M., &amp; Jenkins, A. L. (1988). Starchy foods and glycemic 
							index. Diabetes care, 11(2), 149-159.
						</P><P>Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Cotran, Ramzi S. ; Robbins, Stanley L. 
							(2005). Robbins and Cotran Pathologic Basis of Disease (7th ed.). Philadelphia, 
							Pa.: Saunders. pp. 1194–1195. ISBN 0-7216-0187-1. Lancet. 1998 Sep 12; 
							352(9131):837-53.
						</P><P>Kundig, W., Ghosh, S., &amp; Roseman, S. (1964). PHOSPHATE BOUND TO HISTIDINE 
							IN A PROTEIN AS AN INTERMEDIATE IN A NOVEL PHOSPHO-
							TRANSFERASE SYSTEM. Proceedings of the National Academy of Sciences of 
							the United States of America, 52, 1067–1074.
						</P><P>Lebovitz, H. E. (1997). ALPHA-GLUCOSIDASE INHIBITORS. Endocrinology and 
							Metabolism Clinics of North America, 26(3), 539–551. 
							http://doi.org/10.1016/S0889-8529(05)70266-8
						</P><P>Lourens-Hattingh, A., &amp; Viljoen, B. C. (2001). Yogurt as probiotic carrier food. 
							International Dairy Journal, 11(1–2), 1–17. http://doi.org/10.1016/S0958-
							6946(01)00036-X
						</P><P>Malagelada, J. R., Bazzoli, F., Elewaut, A., Fried, M., Krabshuis, J. H., Lindberg, G., ... 
							Vakil, N. (2007). World Gastroenterology Organisation Practice Guidelines. 
							Dysphagia. Retrieved from http://almacen-
							gpc.dynalias.org/publico/Dysphagia%20WGO%202004%20Ingles.pdf
						</P><P>Man, C. D., Camilleri, M., &amp; Cobelli, C. (2006). A System Model of Oral Glucose 
							Absorption: Validation on Gold Standard Data. IEEE Transactions on Biomedical 
							Engineering, 53(12), 2472–2478. http://doi.org/10.1109/TBME.2006.883792
						</P><P>Meigs, J. B., Nathan, D. M., Wilson, P. W., Cupples, L. A., &amp; Singer, D. E. (1998). 
							Metabolic risk factors worsen continuously across the spectrum of nondiabetic 
							glucose tolerance. The Framingham Offspring Study. Annals of Internal Medicine, 
							128(7), 524–533.
						</P><P>Narimasa, S., Tatsuo, H., Mitsutaka, Y., &amp; Toshio, I. (1979). Action of human pancreatic 
							and salivary α-amylases on maltooligosaccharides: Evaluation of kinetic 
							parameters. Clinica Chimica Acta, 97(2–3), 253–260. 
							http://doi.org/10.1016/0009-8981(79)90423-6
						</P><P>National Diabetes Data Group. (1979). Classification and Diagnosis of Diabetes Mellitus 
							and Other Categories of Glucose Intolerance. Diabetes, 28(12), 1039–1057. 
							http://doi.org/10.2337/diab.28.12.1039
						</P><P>Nissle, A. (1959). [Explanations of the significance of colonic dysbacteria &amp; the 
							mechanism of action of E. coli therapy (mutaflor)]. Die Medizinische, 4(21), 
							1017–1022.
						</P><P>Parkin, C. G., &amp; Brooks, N. (2002). Is postprandial glucose control important? Is it 
							practical in primary care settings?. Clinical Diabetes, 20(2), 71-76.
						</P><P>Patterson, Joan (2013). Many Schools Cutting Back on Physical Education. Las Vegas 
							Review - Journal.
							Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. 
							adults. The Third National Health and Nutrition Examination Survey, 1988-1994.
						</P><P>Peng, C.-K., Buldyrev, S. V., Havlin, S., Simons, M., Stanley, H. E., &amp; Goldberger, A. L. 
							(1994). Mosaic organization of DNA nucleotides. Physical Review E, 49(2), 
							1685–1689. http://doi.org/10.1103/PhysRevE.49.1685
						</P><P>Rathmann, W., &amp; Giani, G. (2004). Global Prevalence of Diabetes: Estimates for the 
							Year 2000 and Projections for 2030: Response to Wild et al. Diabetes Care, 2568-
							2569. 
						</P><P>Recorbet, G. H. I. S. L. A. I. N. E., Robert, C., Givaudan, A., Kudla, B., Normand, P., &amp; 
							Faurie, G. (1993). Conditional suicide system of Escherichia coli released into 
							soil that uses the Bacillus subtilis sacB gene. Applied and environmental 
							microbiology, 59(5), 1361-1366.
						</P><P>Ried, J. L., and A. Collmer. 1987. An nptI-sacB-sacR cartridge for constructing directed, 
							unmarked mutations in Gram-negative bacteria by marker exchange-eviction 
							mutagenesis. Gene 57:239–246.
						</P><P>Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., &amp; Kolterman, O. (2007). 
							Pramlintide Improved Glycemic Control and Reduced Weight in Patients With 
							Type 2 Diabetes Using Basal Insulin. Diabetes Care, 30(11), 2794–2799. 
							http://doi.org/10.2337/dc07-0589
						</P><P>Saydah, S. H., Miret, M., Sung, J., Varas, C., Gause, D., &amp; Brancati, F. L. (2001). 
							Postchallenge Hyperglycemia and Mortality in a National Sample of U.S. Adults. 
							Diabetes Care, 24(8), 1397–1402. http://doi.org/10.2337/diacare.24.8.1397
						</P><P>Snelling, Anatasia; Korba, Casey; Burkey, Alyvia (2007). The National School Lunch 
							and Competitive Food Offerings and Purchasing Behaviors of High School 
							Students, 77(10), 701-705.
						</P><P>Sonnenborn, Ulrich; Schulze, Jurgen. 2009. The Non-Pathogenic Escherichia coli strain 
							Nissle 1917 - Features of a Versatile Probiotic. Microbial Ecology in Health and 
							Disease, (21), 122-158.
						</P><P>S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso, Mortality from coronary 
							heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and 
							without prior myocardial infarction, N Engl J Med, 339 (1998), pp. 229–234
						</P><P>Schultz, M. (2008). Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. 
							Inflammatory Bowel Diseases, 14(7), 1012–1018. 
							http://doi.org/10.1002/ibd.20377
						</P><P>Seifter, S., &amp; Dayton, S. (1950). The estimation of glycogen with the anthrone reagent. 
							Archives of Biochemistry, 25(1), 191–200.
						</P><P>Shulman, N. B., Martinez, B., Brogan, D., Carr, A. A., &amp; Miles, C. G. (1986). Financial 
							cost as an obstacle to hypertension therapy. American Journal of Public Health, 
							76(9), 1105–1108.
						</P><P>Suwattee, P., Lynch, J. C., &amp; Pendergrass, M. L. (2003). Quality of Care for Diabetic 
							Patients in a Large Urban Public Hospital. Diabetes Care, 26(3), 563–568. 
							http://doi.org/10.2337/diacare.26.3.563
						</P><P>Temelkova-Kurktschiev, T. S., Koehler, C., Henkel, E., Leonhardt, W., Fuecker, K., &amp; 
							Hanefeld, M. (2000). Postchallenge plasma glucose and glycemic spikes are more 
							strongly associated with atherosclerosis than fasting glucose or HbA1c level. 
						</P><P>Diabetes Care, 23(12), 1830–1834. http://doi.org/10.2337/diacare.23.12.1830
							What are normal blood glucose levels? Retrieved from Virginia Mason Medical Center 
							website: https://www.virginiamason.org/whatarenormalbloodglucoselevels. 
							Accessed: May. 5th ,2015
						</P></DIV></DIV></DIV><DIV class="learn-more"><DIV class="container"><DIV class="box" id="b1"><A href="/Team:Virginia/Team"><P>TEAM</P></A></DIV><DIV class="box" id="b2"><A href="/Team:Virginia/Project"><P>PROJECT</P></A></DIV><DIV class="box" id="b3"><A href="/Team:Virginia/Practices"><P>POLICY AND PRACTICES</P></A></DIV><DIV class="box" id="b4"><A href="/Team:Virginia/Attributions"><P>ATTRIBUTIONS</P></A></DIV><DIV class="box" id="b5"><A href="/Team:Virginia/Attributions"><P>CONTACT US</P></A></DIV><DIV class="box" id="b6"><A href="#"><P>ABOUT</P></A></DIV></DIV></DIV></DIV></DIV><FOOTER><DIV id="foot-text"><P>University of Virginia iGEM</P><P>148 Gilmer Hall</P><P>485 McCormick Road</P><P>Charlottesville, Virginia 22904</P><P>United States of America</P><P><A href="mailto:virginia.igem@gmail.com">
					virginia.igem@gmail.com</A></P></DIV></FOOTER></DIV></DIV></DIV></BODY></HTML>